 |
市场调查报告书
商品编码
1190091
生物工艺容器市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)Bioprocess Containers Market - Growth, Trends, and Forecasts (2023 - 2028) |
||||||
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
在预测期内，生物工艺容器市场预计将以 12.2% 的复合年增长率增长。
最初，COVID-19 大流行的出现对生物工艺容器市场产生了重大影响，因为世界各地的封锁影响了设备、原材料和其他所需产品的供应链。针对 COVID- 19个正在引起关注。 此外，由于生物工艺容器在疫苗的研发和生产中发挥着非常重要的作用，私人公司和政府机构对疫苗进行了巨额投资，对市场产生了重大影响。 例如，2021 年 7 月发布的 PubMed 数据显示，流行病防范创新联盟 (CEPI) 已投资 56 亿美元开发 COVID-19 疫苗，其中约有 511 亿美元的预购协议 (APA)。花费。 因此，在如此巨大的投资下，疫情对所研究的市场产生了相当大的积极影响。
市场增长的主要驱动因素是全球癌症和免疫疾病病例的流行率不断上升，需要疫苗和生物製剂，免疫疗法和化学疗法刺激了对生物工艺容器的需求，同时人们对生物工艺容器的偏好也在增加。 例如，根据美国癌症协会 2022 年 4 月的一份报告，生物製剂以多种方式用于治疗癌症，并被广泛用于治疗。
此外，2022年8月，中国的信达生物和总部位于巴黎的赛诺菲向生物製药集团投资24.2亿美元，共同在中国开发两种抗癌药物。。 信达生物表示，SAR408701（tusamitamab ravtansine）用于治疗肺癌、胃癌等多种癌症，SAR444245（non-alpha IL-2）用于皮肤癌、头颈肿瘤等的II期临床试验。被告知它在里面。 因此，癌症负担的增加和治疗药物开发的资金预计将推动被调查市场的增长。
此外，该地区公司的其他业务扩张努力（例如扩张、合併、收购和合作）预计将在预测期内进一步推动生物工艺容器市场的增长。 例如，2022 年 6 月，阿斯利康罕见病部门亚力兄宣布，将在未来 18 个月内斥资约 6500 万欧元（68□□20 万美元）扩大其在爱尔兰的製造能力，这笔投资将被该公司用于提高其在该国的生物製剂製造能力，并推动其研发计划。 生物工艺容器可以很容易地集成到生物製剂製造中的各种高性能係统中。 因此，由于上述因素，预计在预测期内对生物过程容器的需求将增加，市场有望增长。
此外，疫苗是用于治疗各种疾病的最重要的生物製剂形式之一，公司正在大力投资开发针对包括罕见病在内的多种疾病的疫苗。因此，有望进一步推动市场增长。 例如，2021 年 10 月，瑞典投资公司 Flerie Invest 投资 5200 万美元，在瑞典北部的 Matfors 建立先进疫苗和生物製剂的创新中心。 疫苗生产需要更好的液体处理设备来满足无污染需求。 生物工艺容器满足这些参数，增加了它们对疫苗生产的需求。
因此，由于上述因素，预计生物过程容器市场在预测期内将会增长。 然而，与设备相关的高成本加上□□可浸出/可提取的相关杂质问题和严格的法规预计将在预测期内限制生物工艺容器市场的增长。
主要市场趋势
在预测期内，二维生物工艺容器部分预计将占据主要市场份额
由于 2D 生物工艺容器部分能够加快现有的生物製药生产过程，并且有助于介质製备、流体管理和产品储存，因此预计将在调查的市场中占据很大份额。
二维生物工艺容器广泛用于散装药物和散装药物前体的细胞采集和输送。 因此，对开发和扩大生物製品生产的投资预计将增加对二维生物工艺容器的需求，从而有望推动该领域的增长。 多家公司提供先进的 2D 生物工艺容器，包括 Thermo Fisher、Servios 和 Cole Palmer。
对更多生物製剂开发和生产的投资不断增加，迫使生物工艺容器製造商加强其产品和扩大生产能力，这将对二维生物工艺容器领域产生积极影响。 例如，2022 年 2 月，ALLpaQ 包装集团宣布推出全新系列的 ALLpaQ 500 PLUS 生物工艺容器。 公司宣布将对生物工艺容器进行投资，以引领市场并满足客户需求。
因此，随着主要参与者投资生物工艺容器业务，预计该领域在未来几年将呈现强劲增长。
预计在预测期内北美地区将占据主要市场份额
北美地区是一些最大的製药和生物製品公司的所在地，这些公司积极从事生物製品的开发和生产。
此外，由于政府的举措，慢性病的高负担和对生物製药的高需求也有望推动市场增长。 例如，2021 年 5 月，魁北克省成为加拿大第四个实施强制性生物仿製药转换计划的省份。 除了一些例外，该州已转为仅允许其批准的生物製剂清单上的生物仿製药（如果有）的政策。 因此，这些努力有望促进生物製剂的采用，并对生物工艺容器市场产生重大积极影响，推动市场增长。
在北美地区，由于美国对生物製剂的大量投资和大量的生物製剂批准以及慢性病负担的增加，美国在生物工艺容器市场占有非常大的市场份额。预计占据 例如，2021 年 7 月，Cytiva 和 Pall Corporation 计划在两年内投资约 15 亿美元扩大产能，以满足对生物技术产品不断增长的需求。 根据 Cytiva 的新闻稿，在包括中国、欧洲和美国在内的亚太地区，层析树脂的价值超过 6 亿美元，细胞培养基的价值超过 4 亿美元，生物反应器等一次性技术的价值超过 3 亿美元。计划投资超过2亿美元扩大其在
同样，2022 年 4 月，Catalent 宣布计划在其位于印第安纳州布卢明顿的工厂投资约 3.5 亿美元，以扩大其生物原料药和产品製造能力。底部。 该项目通过增加新的生物反应器、注射器灌装线和由质量控制实验室和復杂的自动化包装支持的冷冻干燥能力，解决了行业强大的跨模式生物製剂管道。
因此，由于上述因素，预计北美地区将在生物工艺容器市场占据主要份额，其中美国是预测期内生物工艺容器的主要市场。
竞争格局
全球生物工艺容器市场竞争适中。 目前在市场份额方面占据市场主导地位的几家知名企业正在收购产品，与其他企业合作以巩固其在全球市场的地位，并推出新产品。 目前主导市场的公司包括 Thermo Fisher Scientific Inc、Danaher Corporation (Cytiva)、Saint-Gobain S.A、Lonza Group AG 和 Avantor Inc。
其他好处
- Excel 格式的市场预测 (ME) 表
- 三个月的分析师支持
内容
第1章介绍
- 研究假设和市场定义
- 调查范围
第2章研究方法论
第 3 章执行摘要
第4章市场动态
- 市场概览
- 市场驱动力
- 增加对生物製品的需求并降低交叉污染的风险
- 使用一次性技术生产疫苗
- 市场製约因素
- 设备成本高以及与可浸出物/可萃取物相关的杂质问题
- 针对使用生物工艺容器的製造设施制定严格的监管框架
- 波特的五力分析
- 新进入者的威胁
- 买方/消费者议价能力
- 供应商的议价能力
- 替代品的威胁
- 竞争公司之间的敌对关係
第 5 章市场细分
- 按容器类型
- 二维生物工艺容器
- 3D 生物工艺容器
- 其他容器和配件
- 通过使用
- 上游过程
- 下游过程
- 流程开发
- 最终用户
- 生物製药公司
- 生命科学研究与开发公司
- 其他最终用户
- 按地区细分
- 北美
- 美国
- 加拿大
- 墨西哥
- 欧洲
- 德国
- 英国
- 法国
- 意大利
- 西班牙
- 其他欧洲地区
- 亚太地区
- 中国
- 日本
- 印度
- 澳大利亚
- 韩国
- 其他亚太地区
- 中东和非洲
- 海湾合作委员会
- 南非
- 其他中东地区
- 南美洲地区
- 巴西
- 阿根廷
- 其他南美洲
- 北美
第6章竞争格局
- 公司简介
- Thermo Fisher Scientific Inc.
- Cytiva
- Saint-Gobain S.A
- Lonza Group AG
- Avantor Inc
- Merck KGaA
- Sartorius AG
- CellBios Healthcare and Lifesciences Pvt Ltd
- Cole-Parmer Instrument Co
- Biomass Sensor Singapore Pte
第7章 市场机会与今后动向
The bioprocess containers market is anticipated to grow at a CAGR of 12.2% over the forecast period.
Initially, the emergence of the COVID-19 pandemic had a significant impact on the bioprocess containers market because lockdowns all over the globe affected the supply chain of instruments, raw materials, and other necessary products but research & development activities came into focus for the development of a vaccine against COVID-19. There was also huge investments by the various private as well as government entities in the area for the vaccines which had a significant impact on the market because bioprocess containers played a very crucial role in the vaccine development and production. For instance, data from PubMed published in July 2021 stated that Coalition for Epidemic Preparedness Innovations (CEPI) invested USD 5.6 billion in developing COVID-19 vaccines and about USD 51.1 billion was spent on advanced purchase agreements (APAs). Hence, with such huge investments, the pandemic had a considerable positive impact on the market studied.
The major factors attributing to the market's growth include the rising global prevalence of cancer and immunological disorder cases that necessitate the requirement for vaccines and biologics, coupled with the increased preference for immunotherapy and chemotherapy that fuels the demand for bioprocess containers. For instance, according to the April 2022 report of the American Cancer Society, biologics are used in the treatment of cancer in many ways and are being used widely for the treatment.
Additionally, in August 2022, Innovent Biologics of China and Paris-based Sanofi invested USD 2.42 billion in the biopharma group to jointly develop two cancer drugs in China. As per Innovent Biologics, SAR408701, or tusamitamab ravtansine, would be used to treat lung, gastric and other cancers, while SAR444245, or non-alpha IL-2, was under phase-II studies for skin cancer, head, and neck tumors, among others. Hence, the growing burden of cancer and funding in therapeutics development are expected to boost growth in the studied market.
In addition, the other business expansion initiatives by the companies in the area, such as expansion, mergers, acquisitions, and collaborations, are further expected to fuel growth in the bioprocess containers market over the forecast period. For instance, in June 2022, the Rare Disease division of AstraZeneca, Alexion, announced to spend about EUR 65 million (USD 68.20 million) to expand its manufacturing capabilities in Ireland over the next 18 months, the investment will be used by the company to build up its biologics manufacturing capacity and increase R&D initiatives in the country. Bioprocess containers are readily integrated in various high-performance systems during the production of biologics. Hence, owing to the above-mentioned factors, the demand for bioprocess containers is expected to increase over the forecast period and the market is expected to grow.
Furthermore, vaccines are one of the most important forms of biologics that are used in the treatment of various medical conditions, and companies are investing heavily in the development of vaccines for many diseases including rare ones which are further expected to boost the market growth. For instance, in October 2021, the Swedish investment company, Flerie Invest, invested USD 52 million to establish an innovation hub for advanced vaccines and biological drugs in Matfors in northern Sweden. During vaccine production, better liquid handling equipment is required that can manage the neccessity of no-contamination. These parameters are fulfilled by the bioprocess containers which is boosting the demand for the same during vaccine production.
Therefore, due to the above-mentioned factors, the bioprocess containers market is expected to grow over the forecast period. However, the high cost associated with the equipment coupled with impurity issues related to leachable and extractable and strict regulatory regulations are expected to restrain the growth of the bioprocess containers market during the forecast period.
Key Market Trends
2D Bioprocess Containers Segment is Expected to Hold the Major Market Share in the Market Over the Forecast Period
The 2D bioprocess containers segment is anticipated to hold a significant share of the market studied due to their capacity to expedite the existing biopharmaceutical production process and the fact that they are helpful for media preparation, fluid management, and storage of the produce.
For cell harvesting and delivering bulk drug products and bulk drug precursors, 2D bioprocess containers are used widely. Hence, with the investment in the development and expansion of biologics production, the demand for 2D bioprocess containers is expected to increase, which is anticipated to boost the segment's growth. Several companies offer advanced 2D bioprocess containers, such as Thermo Fisher, CellBios, and Cole-Palmer.
The rising investment in developing and producing more biologics is compelling the bioprocess container manufacturers to enhance their offerings and expand their capacity, which is expected to impact the 2D bioprocess containers segment positively. For instance, in February 2022, ALLpaQ Packaging Group announced the launch of its new range of ALLpaQ 500 PLUS Bioprocess Container. The company announced that the investment in bioprocess containers is made to lead the market and fulfill the client's requirements.
Hence, the segment is expected to witness strong growth in the coming years due to the key companies investing in the bioprocessing containers business.
North America Region is Expected to Occupy a Major Market Share in the Market Over the Forecast Period
The North American region is home to some of the largest pharmaceuticals and biopharmaceutical companies that are actively engaged in biologics development and production.
The high demand for biopharmaceutical products owing to the high burden of chronic diseases and government initiatives is also expected to boost the market growth. For instance, in May 2021, Quebec became the fourth Canadian province to implement a mandatory biosimilar switching program. With some exceptions, the province is switching to a policy of allowing only biosimilars on lists of approved biologics, if available. Hence, such initiatives promote the adoption of biologics which is expected to have a significant positive impact on the bioprocess containers market and fuel growth in the market.
In the North American region, United States is expected to hold a very significant market share in the bioprocess containers market owing to the massive investment in biologics and the high number of biologics approval in the country coupled with the rising burden of chronic diseases. For instance, in July 2021, Cytiva and Pall Corporation planned to invest about USD 1.5 billion over two years to expand their capacity to meet the growing demand for biotechnology products. As per the press release by Cytiva, over USD 600 million would be invested in chromatography resins, over USD 400 million in cell culture media, over USD 300 million in single-use technology, for example, bioreactors, and over USD 200 million for the expansion of their sites across China and the rest of the Asia-Pacific region, Europe, and United States.
Similarly, in April 2022, Catalent revealed its plan to invest about USD 350 million at its facility in Bloomington, Indiana, to expand biologics drug substance and product manufacturing capabilities. The project will serve the industry's robust biologics pipeline across various modalities with new bioreactors, syringe filling lines, and additional lyophilization capacity, supported by quality control laboratories and complex automated packaging.
Therefore, due to the above-mentioned factors, the North American region is expected to hold a significant share of the bioprocess containers market, with United States being a major market for bioprocess containers over the forecast period.
Competitive Landscape
The global bioprocess containers market is moderately concentrated in terms of competition. Some prominent players currently dominating the market in terms of market share are acquiring the products, entering into partnerships with other companies to consolidate their global market positions, and launching new products. Some companies currently dominating the market are Thermo Fisher Scientific Inc, Danaher Corporation (Cytiva), Saint-Gobain S.A, Lonza Group AG, and Avantor Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Increasing Demand for Biologics and Lower Risk of Cross-Contamination
- 4.2.2 Vaccine Production Using Single-Use Disposable Technologies
- 4.3 Market Restraints
- 4.3.1 High Cost of Equipments Coupled with Impurity Issues Related to Leachables and Extractables
- 4.3.2 Stringent Regulatory Framework for Manufacturing Facilities with Bioprocess Containers
- 4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 By Type of Containers
- 5.1.1 2D Bioprocess Containers
- 5.1.2 3D Bioprocess Containers
- 5.1.3 Other Containers and Accessories
- 5.2 By Application
- 5.2.1 Upstream Process
- 5.2.2 Downstream Process
- 5.2.3 Process Development
- 5.3 By End-User
- 5.3.1 Biopharmaceutical Companies
- 5.3.2 Life Science R&D Companies
- 5.3.3 Other End-Users
- 5.4 By Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
- 5.4.1 North America
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 Thermo Fisher Scientific Inc.
- 6.1.2 Cytiva
- 6.1.3 Saint-Gobain S.A
- 6.1.4 Lonza Group AG
- 6.1.5 Avantor Inc
- 6.1.6 Merck KGaA
- 6.1.7 Sartorius AG
- 6.1.8 CellBios Healthcare and Lifesciences Pvt Ltd
- 6.1.9 Cole-Parmer Instrument Co
- 6.1.10 Biomass Sensor Singapore Pte
